Authors: Xavier Duval, Sylvie van der Werf, Thierry Blanchon, Anne Mosnier, Maude Bouscambert-Duchamp, Annick Tibi, Vincent Enouf, Cécile Charlois-Ou, Corine Vincent, Laurent Andreoletti, Florence Tubach, Bruno Lina, France Mentré, Catherine Leport
DOI: 10.1371/journal.pmed.1000362
Abstract Summary
A randomized trial cut short shows that combining two antiviral drugs—oseltamivir and zanamivir—offers no advantage over using either medication alone for treating seasonal flu in adults. The dual therapy approach failed to improve clinical or virological outcomes compared to monotherapy, suggesting single-drug treatment remains the optimal strategy.
Why Brain? 🧠
Combination therapy with two antiviral drugs for seasonal flu shows no advantage over single-drug treatment in adults, suggesting monotherapy remains the optimal approach for outpatient care.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
